GERMANS TRIAS I PUJOL RESEARCH INSTITUTE IMAGE: IGTP AND AHEAD THERAPEUTICS TEAM view moreCREDIT: IGTP Researchers from Germans Trias i Pujol Research Institute (IGTP) and Ahead Therapeutics SL have been exploring a treatment based on liposome-type nanoparticles to address the autoimmunity of type 1 diabetes for years. A study recently published in the Journal of...
by American Academy of Otolaryngology — Head and Neck Surgery Credit: CC0 Public DomainThe American Academy of Otolaryngology–Head and Neck Surgery Foundation has published the Clinical Practice Guideline: Immunotherapy for Inhalant Allergy in Otolaryngology–Head and Neck Surgery. This clinical practice guideline identifies quality improvement opportunities and provides clinicians trustworthy, evidence-based recommendations on the management of...
by King’s College London Credit: CC0 Public DomainResearchers have revealed a new mechanism of targeted drug treatment used against chronic lymphocytic leukemia, through the promotion of immune cell function, that could be exploited using new anti-cancer immunotherapies. New research has revealed how a class of new medicines used to treat the blood cancer chronic lymphocytic leukemia...
by University of Pittsburgh Universal adaptor SNAP-CAR and SNAP-synNotch receptor function. a A benzylguanine motif (BG) is chemically conjugated to an antibody using a benzylguanine NHS ester. The BG-antibody conjugate then covalently binds to the extracellular SNAPtag enzyme through a self-labeling reaction. b SNAPtag receptors enable the targeting of multiple different antigens using the same receptor...
by Universitat Pompeu Fabra – Barcelona Diagram of the finding. Credit: Cell Reports (2023). DOI: 10.1016/j.celrep.2023.112123 An international study led by researchers from the Infection Biology Laboratory at the UPF Department of Medicine and Life Sciences (MELIS) establishes that one type of dendritic cell is crucial for the success of immunotherapeutic treatments to control chronic viral infections. These dendritic...
AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE (AAAS) In two separate studies, researchers demonstrate how synthetic biology can be used to tackle a difficult issue in cancer immunotherapy: the way immunotherapy-related approaches focused on short-term killing of tumor cells may fail to eradicate tumors because growth of tumors happens on longer timescales. Here, two research groups...
by Duke University Medical Center Schematic of the tumor-intrinsic NLRP3-HSP70 signaling axis and its role in supporting metastatic progression in the lung in response to anti-PD-1 immunotherapy. Credit: B. Theivanthiran, et al., Science Translational Medicine (2022) Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma...
by University of Helsinki Artistic rendering of the surface of a human dendritic cell illustrating sheet-like processes that fold back onto the membrane surface. Credit: National Institutes of Health (NIH) A recent study from the University of Helsinki reveals that inhibiting certain adhesion receptors on the surface of dendritic cells, the main antigen-presenting cells of the...
by Doherty Institute for Infection and Immunity Credit: CC0 Public Domain In a significant step forward in understanding the crucial role tissue-resident memory T (TRM) cells play in the immune system, researchers have for the first time described how the cells behave in different tissues around the body. This discovery adds to the growing knowledge base around...
by La Jolla Institute for Immunology Anti-PD-1 cancer immunotherapies boost the body’s cancer-fighting T cells, but in many patients, suppressive Tfr cells bring that progress to a grinding halt. Credit: La Jolla Institute for Immunology New research led by scientists at La Jolla Institute for Immunology (LJI) and the University of Liverpool may explain why many cancer patients...
